item1.txt
products or services. Revenue is disaggregated into product sales and contract
contracts with third parties. We recognize any such commissions as selling, general,
a period of time using costs incurred as the measurement of progress towards completion.
those fiscal years, which will be fiscal 2020 for us. Early adoption is permitted,
period. Net income per diluted share amounts assume exercise of all stock options.
including money market funds, to be cash equivalents. Gains and losses on marketable
required disclosures about fair-value measurements. Generally accepted accounting
an asset or liability. Generally accepted accounting principles utilize a valuation
of the individual securities. As a result, bonds with a total fair value of $51,558,274
to declines in credit quality. When evaluating for impairment we assess indicators
due to a 67% decrease in contract research and development revenue. The decrease
general, and administrative expense. The increase in research and development
taxes for the quarter, compared to 32% in the prior-year quarter. The decrease
used in financing activities. We currently believe our working capital and cash
securities. All future dividends will be subject to Board approval and subject
significantly increasing risk. To achieve this objective, we maintain our portfolio
obligations, corporate obligations, and money market funds. Available-for-sale
approximately 89% of our total assets. We have not used derivative financial instruments
disclosure. Based on such evaluation, our Chief Executive Officer and Chief Financial
control activities within them. These included the development of new policies


